Boston Scientific only company to offer choice of two distinct drugs on
separate drug-eluting stent platforms
NATICK, Mass., July 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The PROMUS Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corporation by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the PROMUS Stent immediately in the U.S.
The PROMUS Stent expands Boston Scientific's drug-eluting stent (DES) portfolio, which includes the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System (in the U.S. and international markets) and the TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System (in international markets), making Boston Scientific the only company to offer physicians the choice of two distinct drugs (paclitaxel and everolimus) on separate DES platforms.
"The PROMUS Stent has shown outstanding deliverability, low late loss and the potential to reduce the need for re-interventions," said Ted Feldman, M.D., F.S.C.A.I., Director of the Cardiac Catheterization Laboratory at Evanston Northwestern Healthcare in Evanston, Illinois. "These benefits will make the PROMUS Stent an attractive new treatment option for U.S. physicians and their patients."
"FDA approval of the PROMUS Stent fulfills Boston Scientific's promise
of an unprecedented two-drug strategy - two distinct drugs o
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved